Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The company is pointing to a “big hurdle” being cleared in an Alzheimer’s effort that could make testing simpler and more widely available.
THE APEX TIMES
THE APEX TIMES
A market-focused post points to optimism around Eli Lilly’s demand and distribution momentum as pricing pressure continues, but notes management has already indicated net prices will go lower from here.
THE APEX TIMES
The company agreed a new research and collaboration deal with BioArctic, aiming to use the Swedish biotech’s BrainTransporter technology in a potential Alzheimer’s treatment, according to a report on Yahoo Finance.
THE APEX TIMES
A new analysis discussed in market coverage found monthly healthcare costs declined over time for adults over 55, with results suggesting reductions of up to 38 percent among those using Zepbound. The researchers said the models did not include the cost of Zepbound itself.
THE APEX TIMES
Eli Lilly reported results from a real-world study suggesting that people who remained on Zepbound (tirzepatide) for weight management saw lower healthcare costs than those who discontinued, in a population of adults over 55 with overweight or obesity.
THE APEX TIMES
A market recap highlighted that the company’s stock momentum is tied to how reliably it is converting its drug pipeline into profits, not only to the presence of blockbuster therapies.
THE APEX TIMES
The company’s oral obesity franchise extends beyond the U.S., but how European health systems reimburse the therapy may decide whether the expansion meaningfully lifts results.
THE APEX TIMES
In Q2 2026, both Eli Lilly and Novo Nordisk stayed at the center of the weight-loss drug race, but their latest moves diverged sharply: one company raised guidance while the other announced layoffs, pipeline write-downs, and a major price cut.
THE APEX TIMES
The company’s forecast increase outlines management’s confidence, yet the market reaction suggests many investors want clearer proof on demand, timing, or margins before fully repricing the stock.
